For example, the research of Yarchoan et al. (2017) assessed the relationship between the tumor mutational burden and the objective response rate of PD-1/PD-L1 inhibition by pooling the response data from the published studies and the tumor mutational burden for each tumor type, which was provided by Foundation Medicine (Chalmers et al., 2017), and their analysis was that the sequenced tumor specimens may be different from those whose clinical responses were evaluated (Yarchoan et al., 2017). Here, PDCD1 is linked to neoplasm.